Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of February 2020, with a filing date of February 10, 2020. The report addresses corporate governance changes and the rescheduling of a shareholder meeting.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate administrative matters.
Material Changes
- Meeting Reschedule: The Annual General Meeting of Shareholders, originally scheduled for February 11, 2020, has been rescheduled to March 24, 2020, at 4:00 p.m. Israel time.
- Board Nomination Change: Due to a change in circumstances, the Company determined that Mr. Samuel Moed might not be able to continue serving as an external director. Consequently, the Company nominated Mr. Adi Raviv as an external director in his stead.
- Director Status: Mr. Moed will remain a nominee to serve on the board of directors in the class previously designated for Mr. Raviv.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed relates to the potential inability of a specific director to serve in an external capacity, necessitating a change in nomination.
Key Facts for Investor Verification
- Verify the new date and location for the Annual General Meeting (March 24, 2020, Tel Aviv).
- Confirm the final composition of the board of directors following the nomination of Mr. Adi Raviv and the status of Mr. Samuel Moed.
- Review the revised Notice of Annual General Meeting provided as Exhibit 99.1.